from 0% to 100%; the higher the score, the greater the amount of scalp hair loss. In all, patients were treated by 2 different physicians (M.P. and W.B.) from January 10, 2015, to April 30, 2016.
Results | We identified 13 patients with AA who were or are being treated with tofacitinib. The mean (SD) pretreatment scalp hair loss was 93% (11.5), with 2 patients having alopecia totalis (Figure, A) and 7 patients having alopecia universalis. Regrowth rate-(final SALT score − initial SALT score)/(initial SALT score) × 100-ranged from 2% to 90%, with a mean (SD) of 44.3% (31.9) and a median (range) of 50.5% (90 [0-90]) (Table) . Seven patients (53.8%) achieved a regrowth of at least 50% (Figure, B) . Response time-time from initiation of treatment to any sign of hair regrowth-ranged from 1 to 9 months, with a mean (SD) of 4.2 (2.6) months.
One patient developed a morbilliform eruption and peripheral edema that led to medication withdrawal. Two patients stopped therapy after 3 months because of loss of insurance and within 2 weeks experienced a shed that led back to baseline levels. The remaining 11 patients continued treatment. Of note, 2 patients demonstrated lipid and liver abnormalities that were resolved when the dose was reduced (Table) .
Discussion | Janus kinase inhibitors have been shown to attenuate the inflammatory cascade associated with AA. 1 Our results indicate that tofacitinib is efficacious in the treatment of AA. Although small, our cohort achieved greater median improvement in SALT scores than reported in previously published studies (50.5% vs 21%). 3 This outcome may be related to our higher doses, longer duration of therapy, and patients' shorter duration of current disease episode. In addition, our results demonstrate lack of durability of effect after the discontinuation of therapy, a finding similar to that in other studies. Limitations of this study included the absence of a control group, which prevented the comparison of tofacitinib with a placebo, and the small sample size, which precluded subgroup analyses. In retrospect, the daily doses could have been lower and increased more gradually yet still achieved similar results given that patient response seemed to be both dose and time dependent.
3 Dosages higher than 10 mg twice a day may be associated with higher risk for serious infections and malignant neoplasms, which have been reported at baseline dosages of 5 mg twice daily.
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Conclusions | Oral tofacitinib is a successful treatment for AA, but its efficacy varies widely. To truly assess efficacy, therapeutic trials should continue in the clinical setting for a minimum of 4 months and potentially up to 1 year. Patients should be informed of the lack of durability of effects after the treatment is discontinued. Future studies, including those 6 using other Janus kinase inhibitors, such as ruxolitinib phosphate, are needed and should continue to elucidate these medications' efficacy, safety, and durability in the treatment of AA.
Rates of Dermoscopy Use for Melanoma Diagnosis in the Miami VA Medical Center
In the past 25 years, dermoscopy has had a major impact on the diagnosis of cutaneous lesions. Adequate dermoscopy training can be cost-effective and reduce melanomaassociated morbidity and mortality. 1 Since 2006, dermatoscopes have been provided to incoming dermatology residents at the University of Miami as a part of the training curriculum in addition to didactic dermoscopy training by a pigmented lesion expert.
Methods | We sought to determine the rates of dermoscopy use in melanoma detection at the Miami Veterans Affairs Figure) . There was an inverse correlation between dermoscopy use and Breslow depth with significantly thinner melanomas associated with dermoscopy-use cases compared to nondermoscopy use cases (median Breslow depth 0 mm vs 0.26 mm; Wilcoxon rank-sum test, P < .001).
Discussion | Similar to the trend seen at our training institution, the rates of dermoscopy use have increased over the past 2 decades. In a 2002 survey, 2 only 38% of US dermatology residents reported dermoscopy training during their residency, and more than one-third had never used a dermatoscope. The same group updated their survey in 2010 and noted a 40% increase in the proportion of residency programs that used dermoscopy and 52% increase in those residents receiving training. 3 This same temporal trend has been reported in the United Kingdom: 54% of respondents reported regular dermoscopy use in 2003, compared with 98.5% in 2012. In the United States, dermoscopy users are more likely to be younger, 
